Septerna, Inc. (SEPN) Stock

Septerna, Inc. (SEPN) is a Healthcare stock trading at $36.17 (as of 2026-06-18), with a market capitalization of $1.36B and a trailing P/E of -37.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Septerna, Inc. is a clinical-stage biotechnology company developing oral small-molecule therapies that target G protein-coupled receptors, including programs for endocrine, immunology and inflammation, and metabolic diseases. Its pipeline includes products such as SEP-786 (PTH1R agonist for hypoparathyroidism) and other receptor-targeted candidates for conditions including chronic spontaneous urticaria, Graves’ disease and thyroid eye disease.

Valuation — source: SEC EDGAR (first-party)
Price$36.17
Market Cap$1.36B
P/E Ratio-37.8
EV / EBITDA-23.8
Price / Book3.60
Price / Sales18.84
DCF Value (model)$44.26
DCF Upside vs Price22.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$45.95M
Net Margin-106.4%
Return on Equity-9.5%
Current Ratio4.71
Revenue Growth (YoY)4174.5%
EPS Growth (YoY)-84.8%
FCF Growth (YoY)-257.6%
Financial Health — source: SEC EDGAR
Altman Z-Score4.51 (safe)
Valuation vs Sector & Industry
Stock P/E-37.8
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-280.1%
vs Industry-318.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($168.11M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJeffrey T. Finer
Employees75
CountryUS
IPO Date2024-10-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Amylyx Pharmaceuticals, Inc. (AMLX)
  • Schrödinger, Inc. (SDGR)
  • Palvella Therapeutics, Inc. (PVLA)
  • Savara Inc. (SVRA)
  • Omeros Corporation (OMER)
  • Amphastar Pharmaceuticals, Inc. (AMPH)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • ARS Pharmaceuticals, Inc. (SPRY)
SEPN earnings history · SEPN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.